← boardnext 2029-03
AGIO
Agios Pharmaceuticals, Inc.distress 5/10 · elevated risk$35.86-1%today-21% from 52w high
Rare / Genetic 2
Lead: Sickle Cell Disease · target PK-R · est. market ~$5B (approx, global)
Revenue
$21M
Liquidity
$114M
Runway
0.3 yrs
Shares 1y
+2%
Price & events
+25.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-7.4%
1W
+0.8%
1M
+39.3%
3M
+25.6%
6M
-11.6%
1Y
-27.9%
2Y
-28.6%
5Y
-19.1%
All
Overview
- Market Cap
- $2.13B
- Volume
- 56.38K
- 52 Week Range
- $22.34 – $45.49
- Total Shares
- 59.47M
- Float Shares
- 50.06M
- Short %
- 11.48%
- % Held by Insiders
- 1.12%
- % Held by Institutions
- 109.27%
- RVOL
- 0.05x
- Beta
- 0.54
Pipeline stages · 4 programs
Mitapivat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tebapivat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AG-181
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
[14C]-tebapivat, [13C2, 15N3]-tebapivat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-03 Estimated 50% readout ~2029-05-15 | Phase 3 | Mitapivat | Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | — | not yet recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 3 | Mitapivat | Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | — | not yet recruiting |
| 2029-08 Estimated 50% readout ~2029-10-15 | Phase 3 | Mitapivat | Sickle Cell Disease | — | not yet recruiting |
| 2026-05 | Phase 2 | Tebapivatorphan | Sickle Cell Disease | 59 | active not recruiting |
| 2025-10-30 | Phase 2/3 | Mitapivat | Sickle Cell Disease | 286 | active not recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-10-09 | Phase 1 | AG-181 | Healthy Volunteers | 88 | completed |
| 2025-02-21 | Phase 1 | [14C]-tebapivat, [13C2, 15N3]-tebapivat | Healthy Participants | 8 | completed |
Catalyst news & presentations · 12
- 2026-07-30Confirmed 100%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 1AG-181 · Initiate Phase 1b proof-of-mechanism trial.SEC 8-K
- first half of 2026readoutPhase 1AG-236 · Topline results from Phase 1 healthy volunteer trial.SEC 8-K
- first half of 2026readoutPhase 2tebapivat · Topline results from Phase 2b trial.SEC 8-K
- post-Q1 2026regulatory submissionFiled (NDA/BLA)mitapivat · U.S. marketing application submission following pre-sNDA meeting.SEC 8-K
- January 14, 2026conferencedata presentationsecondaryManagement presentation at 44th Annual J.P. Morgan Healthcare Conference.SEC 8-K
- late 2025readoutPhase 3mitapivat · Topline results from Phase 3 RISE UP study.SEC 8-K
- late 2025enrollment completesecondaryPhase 2tebapivat · Complete patient enrollment in Phase 2b study.SEC 8-K
- September 7, 2025PDUFAPDUFAPYRUKYND (mitapivat) · FDA regulatory decision for supplemental NDA.SEC 8-K
- mid-2025trial initiationsecondaryPhase 2tebapivat · Begin patient enrollment for Phase 2 study.SEC 8-K
- early 2025readoutPhase 3mitapivat · Topline results from Phase 3 ACTIVATE-Kids study.SEC 8-K
- 2025-01-03safety signalmitapivat · FDA approved label update for PYRUKYND adding liver injury warnings from another condition.SEC 8-K
Approved drugs (1)
- PYRUKYNDMITAPIVAT SULFATE2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $43 (+19% upside) · 8 analysts
- 2026-07-21HC Wainwright & Co.Buy
- 2026-07-07Truist SecuritiesBuy
- 2026-07-07RBC CapitalSector Perform
- 2026-07-07B of A SecuritiesBuy
- 2026-06-15HC Wainwright & Co.Buy
- 2026-06-11JP MorganNeutral
Competitors — PK-R
- none identified
Recent news
- 2026-07-22AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - TradingView
- 2026-07-22H.C. Wainwright lowers Agios Pharma price target to $52 on trial data - Investing.com
- 2026-07-22Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Resul - GuruFocus
- 2026-07-22Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus
- 2026-07-22Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus
- 2026-07-21Agios scraps sickle cell treatment after trial shows limited benefit - Reuters
- 2026-07-21Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus
- 2026-07-21Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.